Hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation
Name	Hematopoietic stem cell transplantation
MeshID	D018380
MedlinePlus	003009

Hematopoietic stem cell transplantation. It is a complex medical procedure primarily used to treat various life-threatening diseases of the blood and immune system. The therapy involves the intravenous infusion of hematopoietic stem cells, which are capable of reconstituting a patient's entire blood-forming system. This powerful treatment can be curative for many malignant and non-malignant disorders, though it carries significant risks and requires meticulous supportive care.

Overview

The fundamental goal of the procedure is to replace a patient's diseased or damaged bone marrow with healthy stem cells. These cells can be sourced from the patient themselves or from a donor, with the choice impacting the immunological dynamics of the treatment. Pioneering work by researchers like E. Donnall Thomas at the Fred Hutchinson Cancer Research Center established its viability. The success of the transplant depends heavily on factors such as donor matching, often facilitated by international registries like the National Marrow Donor Program, and the conditioning regimen administered beforehand.

Types of transplantation

The two primary categories are autologous and allogeneic transplantation. In an autologous transplant, the patient's own stem cells are harvested, stored, and reinfused after high-dose therapy, commonly used for diseases like multiple myeloma or lymphoma. Allogeneic transplantation involves stem cells from a genetically matched donor, which can be a sibling, an unrelated volunteer, or cord blood from a bank such as the New York Blood Center. Specialized forms include haploidentical transplants from partially matched relatives and syngeneic transplants from an identical twin. The development of reduced-intensity conditioning regimens has expanded the use of allogeneic transplants to older or less fit patients.

Indications and uses

This therapy is indicated for a wide array of hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome. It is also a standard treatment for severe bone marrow failure states like aplastic anemia and inherited disorders such as severe combined immunodeficiency and thalassemia. Furthermore, it is applied in the management of certain autoimmune diseases and solid tumors. The decision to transplant is guided by protocols from cooperative groups like the European Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research.

Procedure and process

The process begins with a conditioning phase, using chemotherapy and sometimes radiation, to eliminate diseased marrow and suppress the immune system. Stem cells are then collected, typically via apheresis from the peripheral blood after mobilization with agents like filgrastim, or directly from the bone marrow. The infusion is followed by a critical engraftment period, during which patients are highly vulnerable and require intensive support, often in specialized units. Post-transplant care includes prophylaxis against infections and graft-versus-host disease, alongside meticulous monitoring of blood counts and chimerism.

Complications and risks

Major complications are frequent and can be life-threatening. Graft-versus-host disease, where donor immune cells attack the recipient's tissues, is a hallmark challenge of allogeneic transplants. Other significant risks include severe infections during the period of neutropenia, organ toxicity from conditioning regimens (such as hepatic veno-occlusive disease), and relapse of the original disease. Long-term survivors may face issues like chronic graft-versus-host disease, secondary cancers, or endocrine dysfunction. Management of these risks is a focus of ongoing research at institutions like the National Institutes of Health.

Outcomes and prognosis

Prognosis varies dramatically based on disease type, stage, donor match, and patient age. Advances in supportive care, better HLA typing, and improved antimicrobials have steadily increased survival rates over recent decades. Key metrics include overall survival, disease-free survival, and non-relapse mortality. The curative potential often stems from both the conditioning therapy and a potent immunologic graft-versus-tumor effect. Landmark studies from groups like the Dana-Farber Cancer Institute continue to refine prognostic models and treatment strategies to improve long-term outcomes.

History and development

The field's origins trace back to the 1950s with early experiments in radiation biology and the first successful bone marrow transplant between identical twins reported in 1957. The pivotal work of E. Donnall Thomas, for which he received the Nobel Prize in Physiology or Medicine in 1990, demonstrated the feasibility of allogeneic transplantation in humans. Subsequent milestones include the introduction of cyclosporine for graft-versus-host disease prophylaxis, the use of peripheral blood stem cells, and the establishment of international donor registries. Modern developments focus on cellular therapies like CAR-T cell technology and improving access through global collaborations.

Category:Transplantation medicine Category:Hematology Category:Oncology